Immune System News and Research

RSS

ARI-4175 drug may treat colorectal cancer patients with KRAS mutation

When combined with other treatments, the drug cetuximab-which works by slowing or stopping the growth of cancer cells-has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patients-specifically those who carry a mutated form of a gene called KRAS-do not respond to the drug. Researchers at Fox Chase Cancer Center in Philadelphia, however, have been working on a way to overcome this resistance to cetuximab by unleashing a second cetuximab driven mechanism using a novel drug called ARI-4175.

5 Apr 2012

BIND announces data from BIND-014 Phase 1 trials on prostate cancer

Nanomedicine research at the David H. Koch Institute for Integrative Cancer Research at MIT funded by a $5 million grant from the Prostate Cancer Foundation (PCF) has delivered the first nanomedicine shown to successfully target prostate cancer cells and deliver docetaxel chemotherapy in high concentrations in Phase I clinical trials.

5 Apr 2012

Ventria completes VEN100 phase 2 trial on antibiotic-associated diarrhea

Ventria Bioscience has announced the successful completion of a phase 2 clinical trial of its lead therapeutic candidate, VEN100. The study was conducted by a team of investigators from the Department of Epidemiology, Division of Infectious Diseases, and Division of Geriatric Medicine at Johns Hopkins University.

5 Apr 2012

Researchers uncover mechanism that explains link between autoimmunity and atherosclerosis

Patients with autoimmune diseases often show a predisposition to develop "hardening of the arteries" or atherosclerosis. LMU researchers have now uncovered a mechanism that establishes a causal link between the two disorders.

5 Apr 2012

Scientists discover why rapamycin causes diabetic-like symptoms in patients

Scientists at Dana-Farber Cancer Institute have discovered why diabetic-like symptoms develop in some patients given rapamycin, an immune-suppressant drug that also has shown anti-cancer activity and may even slow ageing.

4 Apr 2012

Nuvilex realizes important role for Cell-in-a-Box technology

Nuvilex, Inc., an emerging biotechnology provider of cell and gene therapy solutions through acquisition of SG Austria assets, realizes the important role for Cell-in-a-Box technology and aims to bring to light its use in the production of therapeutic antibodies for clinically important diseases.

4 Apr 2012

MedImmune's quadrivalent flu vaccine may protect children

An intranasal vaccine that includes four weakened strains of influenza could do a better job in protecting children from the flu than current vaccines, Saint Louis University research shows.

4 Apr 2012

FAAN plays a crucial role in supporting peanut allergy study

Why do some children develop a peanut allergy and others don't? Researchers trying to answer this crucial question in order to learn how to prevent this life-threatening food allergy believe that being exposed to peanuts through skin early in life could be a determining factor.

4 Apr 2012

Scientists discover new anti-HCV antibodies

A team led by scientists at The Scripps Research Institute has found antibodies that can prevent infection from widely differing strains of hepatitis C virus (HCV) in cell culture and animal models.

4 Apr 2012

SFU receives NIH grant to develop effective HIV/AIDS vaccine

Jamie Scott, a Simon Fraser University professor and Canada Research Chair in molecular immunity, and three international collaborators are getting a hefty financial boost in their efforts to develop an effective HIV/AIDS vaccine.

4 Apr 2012

Many RA patients more likely to develop lower GI disease

Add lower gastrointestinal (GI) problems such as ulcers, bleeding and perforations to the list of serious complications facing many rheumatoid arthritis patients. They are at greater risk for GI problems and gastrointestinal-related death than people without the disease, a Mayo Clinic study shows.

4 Apr 2012

Vitamin D deficiency may increase risk of mortality in intensive care patients

Scientists have long believed that vitamin D, which is naturally absorbed from sunlight, has an important role in the functioning of the body's autoimmune system. Now Prof. Howard Amital of Tel Aviv University's Sackler Faculty of Medicine and Sheba Medical Center has discovered that the vitamin may also affect the outcomes of patients in intensive care.

4 Apr 2012

Study shows how morphine creates inflammatory response in the brain

An international team of researchers involving the University of Adelaide and University of Colorado has made a major discovery that could lead to more effective treatment of severe pain using morphine.

3 Apr 2012

TLR4/MD-2 protein complex triggers morphine-induced inflammation

A University of Colorado Boulder-led research team has discovered that two protein receptors in the central nervous system team up to respond to morphine and cause unwanted neuroinflammation, a finding with implications for improving the efficacy of the widely used painkiller while decreasing its abuse potential.

3 Apr 2012

Transgenic mice to visualize metastasis and inflammation

One of the major routes of tumor cell dissemination to form metastasis at distant organs in the body is the lymphatic system. To study this process, still poorly understood, and to gain information on which tumors prefer this route for dissemination and how to block it, researchers of the Spanish National Cancer Research Center, led by researcher Sagrario Ortega, have created transgenic mice in which, for the first time, the growth of the lymphatic vessels can be visualized in the whole animal, by a light-emitting reaction, as tumor progresses and forms metastasis.

3 Apr 2012

Researchers discover regulation and functional significance of acute phase response during pneumonia

Researchers at Boston University School of Medicine (BUSM) have discovered the regulation and functional significance of the acute phase response during a lung infection. The findings, which will be published in the May edition of the Journal of Clinical Investigation, demonstrate that the liver responds in order to increase defenses in the blood that prevent localized infections from spreading throughout the body.

3 Apr 2012

Scientists discover new serine protease: NSP4

Neutrophil granulocytes comprise important defences for the immune system. When pathogenic bacteria penetrate the body, they are the first on the scene to mobilise other immune cells via signal molecules, thereby containing the risk. To this end, they release serine proteases - enzymes that cut up other proteins to activate signal molecules. Scientists at the Max Planck Institute of Neurobiology in Martinsried have now discovered a new serine protease: neutrophil serine protease 4, or NSP4.

3 Apr 2012

Merck announces data from ZOSTAVAX Phase III study on shingles

Merck, known as MSD outside the United States and Canada, announced today that data from the pivotal Phase III study with ZOSTAVAX(Zoster Vaccine Live) in adults ages 50 to 59 were published in the April 1 issue of Clinical Infectious Diseases.

3 Apr 2012

FDA clears Fenwal's TPE on the Amicus separator

The U.S. Food and Drug Administration has cleared Fenwal to market a therapeutic plasma exchange protocol for the company's Amicus separator, Fenwal announced today.

3 Apr 2012

Special fatty molecules pave novel way to treat infections, autoimmune diseases, allergies and cancer

An international research team led by scientists from Singapore Immunology Network (SIgN) under the Agency of Science, Technology and Research (A*STAR) discovered that a special class of fatty molecules is essential for activating a unique group of early-responding immune cells.

2 Apr 2012